摘要
目的:了解c-erbB-2、ER及PR在肝细胞癌及正常肝组织中的表达及意义,探讨肝癌治疗中应用c-erbB-2单克隆抗体靶向治疗及内分泌治疗的可能性。方法:采用免疫组织化学SP法检测35例肝细胞癌组织及10例正常肝组织中c-erbB-2、ER及PR的表达,并对35例肝细胞癌患者的1年存活情况进行随访。结果:35例肝细胞癌患者中27例(27/35,77.14%)c-erbB-2阳性表达,ER与PR均为阴性表达。正常肝组织中1例(1/10,10%)c-erbB-2弱阳性表达,ER与PR均为阴性表达。c-erbB-2的表达在肝细胞癌组织和正常肝组织之间存在显著性差异(P<0.005)。c-erbB-2在年龄≤45岁的肝细胞癌患者中阳性表达率为100%(14/14),在年龄>45岁的患者中阳性表达率为61.9%(13/21),二者存在显著性差异(P=0.009)。c-erbB-2的表达与病理特征如性别、肿瘤大小、肿瘤部位、病理分级、临床分期、门脉侵犯、淋巴转移、血清AFP水平和HBV感染无关(P>0.05),与肝细胞癌患者1年生存率有关(P=0.049)。结论:c-erbB-2在肝细胞癌中的表达率明显升高,与肝细胞癌患者发病年龄小、预后差有关。提示c-erbB-2可作为判断肝细胞癌预后的指标及靶向治疗的新靶点。ER与PR在各种组织中表达均为阴性,提示内分泌治疗在肝癌治疗中的作用尚需进一步的研究。
Objective：To elucidate the clinical significance of c-erbB-2,ER and PR in hepatocellular carcinoma （HCC） and the possibility of targeted immunotherapy and hormonal therapy in HCC.Methods：Immunohistochemistry staining was used to detect the expression of c-erbB-2,ER and PR in 35 cases of hepatocellular carcinoma and 10 cases of healthy control.And all the cases of hepatocellular carcinoma were followed-up for 1 year.Results：c-erbB-2 was expressed in 77.14％ （27/35） HCC examined and 10％ （1/10） healthy control.There was great difference between the two groups （P ＜ 0.005）.Neither ER nor PR expression was detected in all the samples.In HCC patients,the expression of c-erbB-2 was related to age （≤45 years vs ＞45 years =100％ vs 61.9％,P=0.009） and 1-year survival （P =0.049）,but had no relationship with other clinical pathologic features （sex,size,grade,clinical stage,invasion of the portal vein,lymph node metastasis）,infection of HBV and the level of serum AFP （P ＞ 0.05）.Conclusion：c-erbB-2 was overexpressed in HCC,which indicated that c-erbB-2 might be one of the independent prognosis factors for HCC and the new target of treatment.Neither ER nor PR expression was detected in all the samples,which indicated that hormonal therapy in HCC needed further investigation.
出处
《现代肿瘤医学》
CAS
2013年第9期2029-2032,共4页
Journal of Modern Oncology
基金
陕西省科技攻关项目资助项目(编号:2002K10-G1)
